Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

Kymera Therapeutics stock

KYMR
US5015751044

Price

46.47
Today +/-
+0.28
Today %
+0.65 %
P

Kymera Therapeutics stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Kymera Therapeutics stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Kymera Therapeutics stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Kymera Therapeutics stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Kymera Therapeutics's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Kymera Therapeutics Stock Price History

DateKymera Therapeutics Price
11/1/202446.47 undefined
10/31/202446.17 undefined
10/30/202447.67 undefined
10/29/202448.49 undefined
10/28/202449.08 undefined
10/25/202447.99 undefined
10/24/202448.73 undefined
10/23/202448.76 undefined
10/22/202448.37 undefined
10/21/202446.56 undefined
10/18/202446.41 undefined
10/17/202446.25 undefined
10/16/202449.02 undefined
10/15/202444.80 undefined
10/14/202446.05 undefined
10/11/202445.02 undefined
10/10/202443.24 undefined
10/9/202443.34 undefined
10/8/202443.04 undefined
10/7/202442.21 undefined

Kymera Therapeutics Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Kymera Therapeutics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Kymera Therapeutics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Kymera Therapeutics’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Kymera Therapeutics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Kymera Therapeutics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Kymera Therapeutics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Kymera Therapeutics’s growth potential.

Kymera Therapeutics Revenue, EBIT and net profit per share

DateKymera Therapeutics RevenueKymera Therapeutics EBITKymera Therapeutics Net Income
2029e1.01 B undefined0 undefined371.2 M undefined
2028e219.94 M undefined-152.66 M undefined-129.32 M undefined
2027e118.17 M undefined-213.31 M undefined-190.02 M undefined
2026e73.81 M undefined-290.41 M undefined-223.16 M undefined
2025e69.21 M undefined-270.08 M undefined-216.8 M undefined
2024e57.75 M undefined-241.67 M undefined-194.77 M undefined
202378.59 M undefined-165.53 M undefined-146.96 M undefined
202246.83 M undefined-161.26 M undefined-154.81 M undefined
202172.83 M undefined-100.53 M undefined-100.22 M undefined
202034.03 M undefined-46.3 M undefined-54.64 M undefined
20192.93 M undefined-42.21 M undefined-41.25 M undefined
20180 undefined-21.45 M undefined-21.47 M undefined

Kymera Therapeutics Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
2018201920202021202220232024e2025e2026e2027e2028e2029e
000.030.070.050.080.060.070.070.120.221.01
--1,600.00111.76-36.1169.57-26.9221.055.8061.6485.59359.36
------------
000000000000
-21-42-46-100-161-165-241-270-290-213-1520
--2,100.00-135.29-138.89-350.00-211.54-422.81-391.30-397.26-180.51-69.41-
-21-41-54-100-154-146-194-216-223-190-129371
-95.2431.7185.1954.00-5.1932.8811.343.24-14.80-32.11-387.60
43.1443.1444.4847.9953.9358.37000000
------------
Details

Keystats

ⓘ

Revenue and Growth

The Kymera Therapeutics Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Kymera Therapeutics is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (k)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
201820192020202120222023
           
41.392296.2442.4407.2374.88
000.90.12.518.76
00500000
000000
0.40.94.78.79.711.67
41.792.9302.3451.2419.4405.32
2.222.120.721.322.2101.08
00162.5125.2152.361.43
000000
000000
000000
0.21.81.68.19.17.93
2.423.9184.8154.6183.6170.44
44.1116.8487.1605.8603575.76
           
73.4109.10000.01
0.82412.8689.3878.9926.27
-35.2-76.5-128.8-229-383.8-530.75
00-0.1-0.7-4.9-0.55
000000
3934.6283.9459.6490.2394.97
2.13.34.444.37.08
2.27.212.925.129.635.25
0.123.492.762.33642.09
000000
0.30.70.71.11.41.28
4.734.6110.792.571.385.69
0.41.20.61.11.21.3
000000
0.246.392.152.640.493.8
0.647.592.753.741.695.1
5.382.1203.4146.2112.9180.79
44.3116.7487.3605.8603.1575.76
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Kymera Therapeutics provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Kymera Therapeutics's financial health and stability.

Assets

Kymera Therapeutics's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Kymera Therapeutics must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Kymera Therapeutics after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Kymera Therapeutics's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
201820192020202120222023
-21-41-45-100-154-146
001223
000000
256124-61-372
1212557181
000000
000000
-171788-128-153-102
-10-9-1-2-34
-1-16-422-9920139
0-15-413-9823174
000000
0000-10
53352762491544
52342892501534
0013100
000000
3336-45212041
-19.2217.3879.03-130.55-155.93-137.31
000000

Kymera Therapeutics stock margins

The Kymera Therapeutics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Kymera Therapeutics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Kymera Therapeutics.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Kymera Therapeutics's sales revenue. A higher gross margin percentage indicates that the Kymera Therapeutics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Kymera Therapeutics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Kymera Therapeutics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Kymera Therapeutics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Kymera Therapeutics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Kymera Therapeutics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Kymera Therapeutics Margin History

Kymera Therapeutics Gross marginKymera Therapeutics Profit marginKymera Therapeutics EBIT marginKymera Therapeutics Profit margin
2029e0 %0 %36.9 %
2028e0 %-69.41 %-58.8 %
2027e0 %-180.51 %-160.81 %
2026e0 %-393.48 %-302.36 %
2025e0 %-390.25 %-313.26 %
2024e0 %-418.46 %-337.25 %
20230 %-210.62 %-186.99 %
20220 %-344.35 %-330.58 %
20210 %-138.03 %-137.61 %
20200 %-136.06 %-160.56 %
20190 %-1,440.61 %-1,407.85 %
20180 %0 %0 %

Kymera Therapeutics Stock Sales Revenue, EBIT, Earnings per Share

The Kymera Therapeutics earnings per share therefore indicates how much revenue Kymera Therapeutics has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Kymera Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Kymera Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Kymera Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Kymera Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Kymera Therapeutics Revenue, EBIT and net profit per share

DateKymera Therapeutics Sales per ShareKymera Therapeutics EBIT per shareKymera Therapeutics Earnings per Share
2029e15.53 undefined0 undefined5.73 undefined
2028e3.4 undefined0 undefined-2 undefined
2027e1.82 undefined0 undefined-2.93 undefined
2026e1.14 undefined0 undefined-3.45 undefined
2025e1.07 undefined0 undefined-3.35 undefined
2024e0.89 undefined0 undefined-3.01 undefined
20231.35 undefined-2.84 undefined-2.52 undefined
20220.87 undefined-2.99 undefined-2.87 undefined
20211.52 undefined-2.09 undefined-2.09 undefined
20200.77 undefined-1.04 undefined-1.23 undefined
20190.07 undefined-0.98 undefined-0.96 undefined
20180 undefined-0.5 undefined-0.5 undefined

Kymera Therapeutics business model

Kymera Therapeutics is one of the most popular companies on Eulerpool.com.

Kymera Therapeutics Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Kymera Therapeutics historical P/E ratio, EBIT multiple, and P/S ratio

Kymera Therapeutics shares outstanding

The number of shares was Kymera Therapeutics in 2023 — This indicates how many shares 58.366 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Kymera Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Kymera Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Kymera Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Kymera Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

The World’s Best Investors Are On Eulerpool

Unfortunately, there are currently no price targets and forecasts available for Kymera Therapeutics.

Kymera Therapeutics latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
9/30/2024-0.86 -0.82  (4.15 %)2024 Q3
6/30/2024-0.7 -0.58  (16.79 %)2024 Q2
3/31/2024-0.74 -0.62  (16.39 %)2024 Q1
12/31/2023-0.41 -0.25  (39.48 %)2023 Q4
9/30/2023-0.65 -0.9  (-37.57 %)2023 Q3
6/30/2023-0.65 -0.67  (-3.17 %)2023 Q2
3/31/2023-0.69 -0.7  (-1.3 %)2023 Q1
12/31/2022-0.65 -0.6  (7.09 %)2022 Q4
9/30/2022-0.73 -0.79  (-7.82 %)2022 Q3
6/30/2022-0.7 -0.78  (-10.73 %)2022 Q2
1
2

Eulerpool ESG Scorecard© for the Kymera Therapeutics stock

Eulerpool World ESG Rating (EESG©)

72/ 100

🌱 Environment

79

👫 Social

66

🏛️ Governance

71

Environment

Scope 1 - Direct Emissions
Scope 2 - Indirect emissions from purchased energy
Scope 3 - Indirect emissions within the value chain
Total CO₂ emissions
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency

Social

Percentage of female employees
Percentage of women in management
Percentage of Asian employees
Share of Asian management
Percentage of Hispanic/Latino employees
Hispano/Latino Management share
Percentage of Black employees
Black Management Share
Percentage of white employees
White Management Share
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic

Governance (Corporate Governance)

Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Kymera Therapeutics shareholders

%
Name
Stocks
Change
Date
9.74266 % T. Rowe Price Associates, Inc.6,310,32160,4846/30/2024
9.25726 % Baker Bros. Advisors LP5,995,92918/21/2024
8.26065 % Atlas Venture5,350,422-26,9406/30/2024
7.96943 % BVF Partners L.P.5,161,80106/30/2024
7.45228 % Fidelity Management & Research Company LLC4,826,840462,4306/30/2024
7.42980 % The Vanguard Group, Inc.4,812,28352,9326/30/2024
6.65340 % Wellington Management Company, LLP4,309,40515,7086/30/2024
6.00415 % Avoro Capital Advisors LLC3,888,88806/30/2024
5.40703 % BlackRock Institutional Trust Company, N.A.3,502,134340,9286/30/2024
4.64044 % Invus Public Equities Advisors, LLC3,005,610-21,5256/30/2024
1
2
3
4
5
...
10

Kymera Therapeutics Executives and Management Board

Dr. Nello Mainolfi(44)
Kymera Therapeutics President, Chief Executive Officer, Co-Founder, Director (since 2019)
Compensation 6.93 M
Mr. Bruce Jacobs(53)
Kymera Therapeutics Chief Financial Officer
Compensation 2.89 M
Dr. Jared Gollob(59)
Kymera Therapeutics Chief Medical Officer
Compensation 2.77 M
Dr. John Maraganore(60)
Kymera Therapeutics Independent Director
Compensation 577,788
Dr. Victor Sandor(56)
Kymera Therapeutics Independent Director
Compensation 451,253
1
2
3

Most common questions regarding Kymera Therapeutics

What is the P/E ratio of Kymera Therapeutics 2024?

The Kymera Therapeutics P/E ratio is -13.93.

What is the P/S ratio of Kymera Therapeutics 2024?

The Kymera Therapeutics P/S ratio is 46.96.

What is the Quality Investing of Kymera Therapeutics?

The Quality Investing for Kymera Therapeutics is 3/10.

What is the revenue of Kymera Therapeutics 2024?

The expected Kymera Therapeutics revenue is 57.75 M USD.

How high is the profit of Kymera Therapeutics 2024?

The expected Kymera Therapeutics profit is -194.77 M USD.

What is the business model of Kymera Therapeutics

No history available for Kymera Therapeutics.

What is the Kymera Therapeutics dividend?

Kymera Therapeutics pays a dividend of 0 USD distributed over payouts per year.

How often does Kymera Therapeutics pay dividends?

The dividend cannot currently be calculated for Kymera Therapeutics or the company does not pay out a dividend.

What is the Kymera Therapeutics ISIN?

The ISIN of Kymera Therapeutics is US5015751044.

What is the Kymera Therapeutics ticker?

The ticker of Kymera Therapeutics is KYMR.

How much dividend does Kymera Therapeutics pay?

Over the past 12 months, Kymera Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Kymera Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Kymera Therapeutics?

The current dividend yield of Kymera Therapeutics is .

When does Kymera Therapeutics pay dividends?

Kymera Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Kymera Therapeutics?

Kymera Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Kymera Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Kymera Therapeutics located?

Kymera Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Kymera Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Kymera Therapeutics from 11/5/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/5/2024.

When did Kymera Therapeutics pay the last dividend?

The last dividend was paid out on 11/5/2024.

What was the dividend of Kymera Therapeutics in the year 2023?

In the year 2023, Kymera Therapeutics distributed 0 USD as dividends.

In which currency does Kymera Therapeutics pay out the dividend?

The dividends of Kymera Therapeutics are distributed in USD.

All fundamentals about Kymera Therapeutics

Our stock analysis for Kymera Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Kymera Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.